Lipid Modification for the Prevention of Cardiovascular Disease (NICE Guideline)

Summary of NICE guidance on lipid lowering with statins.

Alirocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia (TA393)

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia (TA394)

Sacubitril Valsartan for Treating Symptomatic Chronic Heart Failure with Reduced Ejection Fraction (TA388)

Ezetimibe for the Treatment of Primary Heterozygous Familial and Non-Familial Hypercholesterolaemia (TA385)

Current Medical Standards of Fitness to Drive (DVLA Guidance)

Key advice from DVLA on fitness to drive.

Edoxaban for Treating and for Preventing Deep Vein Thrombosis and Pulmonary Embolism (TA354)

Apixaban for the Treatment and Secondary Prevention of Deep Vein Thrombosis and/or Pulmonary Embolism (TA341)

Dabigatran Etexilate for the Treatment and Secondary Prevention of Deep Vein Thrombosis and/or Pulmonary Embolism (TA327)

Prevention of Cardiovascular Disease (Joint British Societies' Guideline)

Recommended assessments, management and targets.

Table: Monitoring Requirements for Hyperlipidaemia Treatments

Tests required for patients on lipid-lowering drugs.

Table: Novel Oral Anticoagulants for the Prevention of Stroke

Dosing of NOACs in non-valvular AF.

Table: Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.